Participated in RyboDyn's $10M seed financing for AI-driven dark-proteome cancer target discovery.
RyboDyn is pioneering immunotherapy development by unlocking the dark proteome with our proprietary RyboCypher™ technology
RyboDyn is pioneering immunotherapy development by unlocking the dark proteome with our proprietary RyboCypher™ technology. We reveal hidden targets that conventional sequencing overlooks, transforming previously unknown biological signals into breakthrough therapies that redefine patient care.